Login
$GANX
$0.94 -$0.00 (0.01%) After hours

Company Executives

Officer Age 2025 pay Source
Gene Mack Also a director
Interim Chief Financial Officer
52 $1,467,139
Jeanette Weidner
See Remarks
Title from the Form 4 dated Oct 29, 2026
Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
5 of 7
stated in the proxy
Average tenure
5.3 years
from year joined
CEO also chairs the board
No
Khalid Islam
Director Age On board Independent Other public boards 2025 pay Source
Khalid Islam
70 2017
9 years
Not independent Fennec Pharmaceuticals Inc., Minoryx Therapeutics S.L. Not stated
Gene Mack
52 2025
1 year
Not independent None stated Paid as CEO
Dov Goldstein
58 2021
5 years
Independent Coya Therapeutics, Inc. $80,150
Hans Peter Hasler
70 2021
5 years
Independent HBM Healthcare Investments AG, Minerva Neuroscience Inc., Shield Therapeutics PLC $76,650
Gwen Melincoff
74 2021
5 years
Independent Protalix Biotherapeutics, Inc. $63,150
Claude Nicaise
73 2021
5 years
Independent Sarepta Therapeutics, Inc., Chemomab Therapeutics Ltd, Cassava Sciences, Inc. $68,150
Jeffrey Riley
63 2019
7 years
Independent None stated $78,650

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

2 disclosed in the proxy filed Apr 28, 2026
Matthias Alder
former Chief Executive Officer
$525,000
2024

Separation agreement with former CEO providing severance payment of twelve months base salary, COBRA premium payments, partial equity vesting, and continued insurance premiums.

Minoryx Therapeutics, S.L.
Dr. Islam, one of our founders and Chairman of our Board, is the chairman of the board of directors of Minoryx
Amount not stated
2024 and 2025

License agreement under which the company licensed intellectual property from Minoryx and agreed to pay royalties; no payments were made in 2025 or 2024.

With Minoryx Therapeutics, S.L. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support